

COLLABORATIVE PROBLEM SOLVING IN NUTRIZIONE CLINICA

Giornate catanesi di nutrizione clinica VI edizione



Con il patrocinio di



Università
di Catania



23-24 Giugno 2022



Casa la Carrubbazza

Via Raffaello Sanzio, 38 - San Gregorio di Catania (CT)

GUT MICROBIOTA E PATOLOGIE CORRELATE

Dr GIAN MARCO GIORGETTI
DIRETTORE UO NUTRIZIONE CLINICA ASL ROMA2


THE GUT MICROBIOTA COMPOSITION

TABLE. Major Bacteria and Archaea Phyla and Genera Found in the Human Gut Microbiota^a

Phyla	Representative genera
Bacteria	
Firmicutes	<i>Ruminococcus</i> <i>Clostridium</i> <i>Peptostreptococcus</i> <i>Lactobacillus</i> <i>Enterococcus</i>
Bacteroidetes	<i>Bacteroides</i>
Proteobacteria	<i>Desulfovibrio</i> <i>Escherichia</i> <i>Helicobacter</i>
Verrucomicrobia ^b	
Actinobacteria	<i>Bifidobacterium</i>
Cyanobacteria ^b	
Synergistes ^b	
Archaea	
Euryarchaeota	<i>Methanobrevibacter</i>

Humans: Meta-organism

10-fold greater numbers of bacterial than animal cells, metabolically and immunologically integrated, with a biomass >1 Kg



<10³ CFU/mL

10²-10⁹ CFU/mL

10⁴-10¹² CFU/mL

GUT MICROBIOTA: only bacteria?

Virome


Bacteriome

Mycobiome

*Mucosal
Barrier*

*Epithelial
barrier*

*Endocrine
system*



*Acquired
and
Innate
immunity*

*Vascular and
lymphatic systems*

*Neuroenteric system
Digestive enzymes*

What role for YEASTS?

Candida from commensal to pathogen

- Yeasts are commensal to the gut at low concentrations
- Candida overgrowth is a consequence of disturbances in the host's defense systems: *antibiotic therapy and change in physiological gut microbiota, pH, partial CO₂ pressure, amino acid availability, iron deficiency...*
- Yeast genome can be modified by repeated point mutations (*«microevolution»*) in order to overcome host protective measures



Thewes S, Mol Microbiol 2007

GUT BACTERIOME

700-800 kg of bacteria, >3.300.000 genes

**8 bacterial divisions (superkingdoms)
95% genes identity**



**>1100 species
Over 99% genes identity**



**>15000 strains
100% genes identity**

Microbiome  **Metabolome**

Leser et al, Environ Microbiol 2011

Qin et al, Nature 2011

GUT mutualistic bacteria characterization

Need for a Molecular Microbiology

Microscopic counts on human faeces suggest that 60 to 80% of the observable bacteria cannot be cultivated




Culture independent methods based on the analysis of the 16S rRNA gene reveals a myriad of novel bacterial lineages within the human gut

Suau et al, Appl Environ Microbiol 1999


GUT MICROBIOTA

Fluorescence in-situ hybridization (FISH) using bacterial 16S rRNA probes showing bacteria localized to the mucus layer.




Taxa prevalenti nel microbioma umano, che sono stati metagenomicamente e tassonomicamente ben definiti nella popolazione HMP.

Mean nonzero abundance (size) and population prevalence (intensity) of microbial clades



L'assetto del microbioma varia tra i soggetti al livello di specie e ceppi.



At birth the human body is sterile

Vaginal microbiota (mother)

Fecal microbiota
(mother)


Skin microbiota
(mother/father/parents/
babysitter)

Diet


Ambient




Native CORE microbiota
(4-36 months of life)



Bacterial diversity increases with age





Review Article

Interactions between Innate Immunity, Microbiota, and Probiotics

**GianMarco Giorgetti,¹ Giovanni Brandimarte,² Federica Fabiocchi,³ Salvatore Ricci,⁴
Paolo Flamini,⁴ Giancarlo Sandri,³ Maria Cristina Trotta,⁵ Walter Elisei,⁶ Antonio Penna,⁷
Piera Giuseppina Lecca,² Marcello Picchio,⁸ and Antonio Tursi⁹**

¹*Digestive Endoscopy & Nutrition Unit, "S. Eugenio" Hospital, Piazzale dell'Umanesimo 10, 00144 Rome, Italy*

²*Division of Internal Medicine and Gastroenterology, "Cristo Re" Hospital, Via delle Calasanziane 25, 00167 Rome, Italy*

³*Clinical Nutrition Unit, "S. Eugenio" Hospital, Piazzale dell'Umanesimo 10, 00144 Rome, Italy*

⁴*Clinical Nutrition Unit, "Umberto I" Hospital, Viale del Policliniucio 185, 00186 Rome, Italy*

⁵*Division of Internal Medicine, "S. Eugenio" Hospital, Piazzale dell'Umanesimo 10, 00144 Rome, Italy*

⁶*Division of Gastroenterology, ASL Roma H, Via Borgo Garibaldi 12, Albano Laziale, 00041 Rome, Italy*

⁷*Division of Gastroenterology, "S. Paolo" Hospital, Contrada Capo Scardicchio 82, 00123 Bari, Italy*

⁸*Division of General Surgery, "P. Colombo" Hospital, ASL Roma H, Via Orti Ginnetti 7, Velletri, 00049 Rome, Italy*

⁹*Gastroenterology Service, ASL BAT, Via Torino 49, 76123 Andria, Italy*

WHEN A DYSBIOISIS OCCURS?

Unbalanced DIET:

High fats

Low fibers

High calories

High meat content





....



DIETA



Percentage composition of Each Intestinal Microflora in Total Counts



ARTICLE


Received 23 May 2014 | Accepted 20 Jan 2015 | Published 28 Apr 2015

DOI: 10.1038/ncomms7342



Fat, fibre and cancer risk in African Americans and rural Africans

Stephen J.D. O'Keefe¹, Jia V. Li², Leo Lahti^{3,4}, Junhai Ou¹, Franck Carbonero^{5,†}, Khaled Mohammed¹, Joram M. Posma², James Kinross², Elaine Wahl¹, Elizabeth Ruder⁶, Kishore Vippera¹, Vasudevan Naidoo⁷, Lungile Mtshali⁷, Sebastian Tims³, Philippe G.B. Puylaert³, James DeLany⁸, Alyssa Krasinskas⁹, Ann C. Benefiel⁵, Hatem O. Kaseb¹, Keith Newton⁷, Jeremy K. Nicholson², Willem M. de Vos^{3,4,10}, H. Rex Gaskins⁵ & Erwin G. Zoetendal³

IMMUNOISTOCHIMICA DELLA MUCOSA DEL COLON DEI BIOMARKERS DI PROLIFERAZIONE E INFIAMMAZIONE




Analisi mirata dei geni funzionali delle specie microbiche di interesse specifico e dei loro metaboliti.




O'Keefe et al.; Fat, Fiber and Cancer Risk in African Americans and Rural Africans; *Nat Commun.* ; 6: 6342; 2015

EFFETTI DEL RA SULL'HOMING E SULLA DIFFERENZIAZIONE DEI LINFOCITI.


CD103+ MLN-DC




RUOLO COMPLEMENTARE DEL RA E DEI SCFA NELLA TOLLERANZA IMMUNITARIA DEL PICCOLO INTESTINO E DEL COLON.





MECCANISMO DI SOPPRESSIONE DEL TUMORE FIBRE E BUTIRRATO-MEDIATA.




Fermentazione dei polisaccaridi nel colon dell'uomo: principali prodotti terminali





**(W. Sheppach MD et al.: Journal of Parenteral and Enteral Nutrition
Vol. 16 n°1 92 by ASPEN)**

CRYPT COMPARTMENT



(W. Sheppach MD et al.:Journal of Parenteral and Enteral Nutrition
Vol. 16 n°1 92 by ASPEN)

HOW THE HOST-GUT MICROBIOTA BALANCE IS MANTAINED?

➤ Secretion of :

Gastric acid

Mucus

Biliary salts

Mucosal Ig


➤ Mucosal pH

➤ Mucosal barrier integrity


➤ Intestinal motility

➤ Local mucosal and systemic immunity

➤ Interactions among different bacteria species



AZIONI DELLA FLORA INTESTINALE IN CONDIZIONI DI DISBIOSI E/O ALTERAZIONE DELLA BARRIERA MUCOSA



ANTIBIOTICI



Impact of antibiotics on the gut microbiota of critically ill patients

Journal of Medical Microbiology (2008), 57, 1007–1014

Gaetano Iapichino,¹ Maria Luisa Callegari,² Silvia Marzorati,¹

Table 3. Antibiotic therapies and microbiota variations in the patient cohort in this study

Results of RT-PCR are expressed as the amounts of bacterial target genomes of *Enterococcus* (g faeces)⁻¹.


Patient	Antibiotics*	Enterococci in T0	Similarity of DGGE profiles T1 vs T0 (%)	Enterococci in T1	Similarity of DGGE profiles T2 vs T0 (%)	Enterococci in T2
1	CTX, CLI, SDD	3.0E + 6	88.0	4.0E + 9	–	
2†	AMP, CTX, CLI, SDD	1.5E + 5	25.0	6.0E + 10	–	
3	CRO, CLR	9.0E + 7	75.0	4.45E + 7	–	
4	CTX, CLR, SDD	6.7E + 6	93.1	7.6E + 6	–	
5†	CTX, CLR, SDD	2.0E + 6	63.0	9.0E + 10	–	
6†	CFZ, CLI	6.7E + 6	62.9	1.3E + 8	57.4	5.6E + 8
7†	CRO, CLR	1.2E + 7	34.4	3.4E + 8	28.0	5.1E + 9
8	CRO, CLR	4.4E + 6	90.0	3.0E + 6	–	
9	CRO, CLR	7.8E + 6	68.0	2.6E + 6	–	
10	CRO, CLI	5.0E + 6	49.9	2.3E + 8	–	
11	CRO, CLR, CLI, OXA, SDD	7.5E + 6	33.3	3.0E + 7	52.2	1.2E + 9
12	AMP, CRO	1.2E + 6	84.7	1.5E + 6	39.4	3.0E + 7
13	CFZ	1.2E + 7	82.2	3.0E + 7	51.2	2.0E + 7
14	CRO, CLR, CLI	8.5E + 7	3.8	4.5E + 9	10.5	7.9E + 10
15	CTX, CLI, SDD	1.2E + 6	77.6	3.0E + 5	48.7	6.0E + 8

*AMP, ampicillin; CFZ, cefazolin; CLI, clindamycin; CLR, clarithromycin; CRO, ceftriaxone; CTX, cefotaxime; OXA, oxacillin; SDD, selective digestive decontamination.

†Died. All deaths were in the ICU.



GUT MICROBIOTA: disbiosi e patologie correlate



Gut-microbiome and Host

IBD

Obesity


Diabetes Mellitus

NASH

Autoimmunity

Cancer

Inflammatory Bowel Disease (IBD): a multifactorial pathogenesis




The crucial role of NOD2


Genetic studies confirm a role for the underlying microbial–host interaction in IBD pathogenesis. These include the genomic regions of nucleotide-binding oligomerisation domain containing 2 (NOD2), which is an intracellular receptor that recognizes proteins found in bacterial cell wall species.

Patients with CD demonstrate an association with the NOD2 gene including three polymorphisms that weaken the host peptidoglycan response. Carriers of NOD2 have a 1.75–4-fold increased risk of CD and are clinically more likely to undergo surgical gastrointestinal (GI) resection.

NOD2 DEFICIENCIES INCREASE INFLAMMATORY RESPONSE TO LPS STIMULATION



- **Decrease in beneficial Firmicutes (clostridia sp)**
 - Species able to induce immune tolerance and reduce colitis in animal models
 - Reduction may permit hyper-immune response
- **Increase in Proteobacteria**
 - Generally aerotolerant
 - Organisms able to manage oxidative stress
 - Injurious in animal models of intestinal inflammation




Spondilite anchilosante



Immagini gentilmente concesse da J Braun, MD

Entesite



Questo è il segno distintivo delle spondiloartropatie
Frequenza di entesiti sintomatiche: 5-30% delle SpA
Predominante coinvolgimento entesale in alcuni casi

Dattilite



Fortemente associata a tenosinovite come evidenziato da MRI¹

Due sottotipi

acuta: rigonfiamento morbido, forte dolore, rossore

cronica: rigonfiamento solido, dolore medio-moderato,

Frequenza: 5-30% delle SpA

Gut-microbiome and Host

IBD

Obesity

Diabetes Mellitus


NASH

Autoimmunity

Cancer

GUT MICROBIOTA AND OBESITY: THE DYSBIOSIS CONCEPT

Obese animals have a 50% reduction of Bacteroidetes and a proportional increase in Firmicutes




Microbial metabolic production

- ✓ Microbial signals also regulate **Fiaf** release from intestinal epithelial cells, which acts as an inhibitor of Lpl and thereby regulates peripheral fat storage
- ✓ Through another unknown mechanism, the microbiota also regulates the energy gauge in the liver and muscle through the phosphorylation of Ampk. Glp2 ascertains epithelial barrier function
- ✓ A **leaky barrier** leads to exposure and activation of myeloid cells in response to microbial signals such as the Tlr4 ligand endotoxin.


GUT MICROBIOTA & REGULATION OF ENERGY STORAGE

- ↓ ➤ *Suppression of Fast Induced Adipose Factor*
- *Stimulation LPL / inhibition LPL inhibitor*
- ↑ ➤ *Increased hepatic lipogenesis and fat storage in adipocytes*




GUT MICROBIOTA and REGULATION OF ENERGY STORAGE

Changes the gut microbiota is associated with a higher gut permeability leading to a higher plasma LPS levels (metabolic endotoxemia)



GUT MICROBIOTA and REGULATION OF ENERGY STORAGE


Metabolic endotoxemia promotes **low-grade inflammation-induced metabolic disorders** (insulin resistance, diabetes, obesity, steatosis, oxidative stress, and adipose tissue macrophage infiltration).



GUT MICROBIOTA and REGULATION OF ENERGY STORAGE



➤ WT mice have 42% more total body fat and 47% more gonadal fat than germ-free (GF) mice, despite lower energy intake

➤ Colonisation of GF mice with microbiota from control mice produces a 60% increase in body fat mass, associated with increased insulin resistance




GUT MICROBIOTA AND OBESITY: THE DYSBIOSIS CONCEPT

- Obese people had **lower Bacteroides** and **more Firmicutes** in distal gut flora than lean control
- Ratio of **Bacteroidetes to Firmicutes** approached a lean type profile after 52 weeks of diet-induced weight loss




GUT MICROBIOTA AND OBESITY: THE DYSBIOSIS CONCEPT

Increase in
Gammaproteobacteria
and proportional
decrease in Firmicutes
after bariatric surgery
(gastric by-pass)



GUT MICROBIOTA AND OBESITY: THE DYSBIOSIS CONCEPT

Switching mice to a High-Fat-Diet drives to a decrease in Bacteroides and an increase in both Firmicutes and Proteobacteria independently of obesity




GUT MICROBIOTA AND OBESITY: THE DYSBIOSIS CONCEPT

- A- WT mice/Low Fat diet
 - B- WT mice/High Fat diet
 - C- Ob/ob mice/ LF diet
- 8 wks

➤ Increase in Firmicutes in both HF-fed and ob/ob mice ($p < 0.05$)

➤ Reductions in Bacteroides in ob/ob mice ($p < 0.001$)



THE CORE GUT MICROBIOME


- No single bacterial phylotype was detectable at an abundant frequency
- The hypothesis of a core human gut microbiome may be incorrect
- A core gut microbiome exists at the level of metabolic functions
- Understanding the underlying principles should provide insights about microbial adaptation to a wide range of environments

Gut-microbiome and Host

- ✓ IBD
- ✓ Obesity
- ✓ **Diabetes Mellitus**
- ✓ NASH
- ✓ Immune system
- ✓ Cancer


GUT MICROBIOTA in TYPE II DIABETES

Gut microbiota modulation improves glucose tolerance by :
reducing the population of gut microbiota



GUT MICROBIOTA in TYPE II DIABETES


Gut microbiota modulation improves glucose tolerance by :
suppressing factors like TNF and LPS



GUT MICROBIOTA in TYPE II DIABETES


Gut microbiota modulation improves glucose tolerance by :

increasing glycogen storage



GUT MICROBIOTA in TYPE II DIABETES


Gut microbiota modulation improves glucose tolerance by :
decreasing triglyceride accumulation by the liver



GUT MICROBIOTA in TYPE II DIABETES


Gut microbiota modulation improves glucose tolerance by :

High adiponectin levels might further enhance the insulin sensitivity




TYPE 2 DIABETES IS ASSOCIATED WITH COMPOSITIONAL CHANGES IN GUT MICROBIOTA.

Betaproteobacteria was highly enriched in diabetic compared to non-diabetic persons ($P = 0.02$) and positively correlated with plasma glucose ($P = 0.04$)



TYPE 2 DIABETES IS ASSOCIATED WITH COMPOSITIONAL CHANGES IN GUT MICROBIOTA.

Ratios of Bacteroidetes to Firmicutes as well as the ratios of Bacteroides-Prevotella group to C. coccoides-E. rectale group correlated positively and significantly with plasma glucose concentration ($P = 0.04$) but not with BMIs



Gut-microbiome and Host

- ✓ IBD
- ✓ Obesity
- ✓ Diabetes Mellitus
- ✓ **NASH**
- ✓ Autoimmunity
- ✓ Cancer


Consequences of the altered microbial/metabolic balance

NAFLD and NASH

NAFLD and NASH are strongly linked to obesity, type 2 diabetes mellitus and the metabolic syndrome and, accordingly, have become common worldwide problems



Small intestinal bacterial overgrowth of Gram-negative organisms could promote insulin resistance, increase endogenous ethanol production and induce potential mediators of this association, lipopolysaccharide



2.3 Steatoepatite non alcolica (NASH) (Figure 8 e 9)






Figura 9



A complex interaction ...



Gut-microbiome and Host

- ✓ IBD
- ✓ Obesity
- ✓ Diabetes Mellitus
- ✓ NASH
- ✓ Autoimmunity
- ✓ Cancer



Review

Molecular Insight into Gut Microbiota and Rheumatoid Arthritis

Xiaohao Wu ^{1,2,†}, Bing He ^{1,2,†}, Jin Liu ^{1,2,†}, Hui Feng ^{3,4,†}, Yinghui Ma ^{3,4}, Defang Li ^{1,2,5}, Baosheng Guo ^{1,2,5}, Chao Liang ^{1,2,5}, Lei Dang ^{1,2}, Luyao Wang ^{1,2}, Jing Tian ⁴, Hailong Zhu ^{1,2,*}, Lianbo Xiao ^{3,4,*}, Cheng Lu ^{1,2,6,*}, Aiping Lu ^{1,2,3,4,5,6,*} and Ge Zhang ^{1,2,4,5,*}

Table 1. Alterations of gut microbiota related with RA.

Studygroups	Sample Type	Technology Employed	Bacterial Taxa (↓low, ↑enriched)	Ref.
Early RA (51) vs. Fibromyalgia (50)	Stool	16S rRNA hybridization, and DNA-staining	↓ <i>Bifidobacteria</i> , ↓ <i>Bacteroides-Porphyrromonas-Prevotella</i> , ↓ <i>Bacteroides fragile</i> , ↓ <i>Clostridium coccoides</i>	[24]
Early RA (15) vs. Healthy (15)	Stool	Quantitative real-time PCR	↑ <i>Lactobacillus</i>	[25]
New-Onset RA (44) vs. Healthy (28)	Stool	16S rRNA gene and WGS sequencing	↑ <i>Prevotella copri</i> , ↓ <i>Bacteroidetes</i>	[26]
RA (30) vs. Healthy (30)	Stool	16S rRNA gene and WGS sequencing	↑ <i>Enterococci</i> , ↑ <i>Clostridia</i> , ↑ <i>Colibacteria</i> , ↓ <i>Lactobacteria</i>	[27]
Treatment-naïve RA (94) vs. Healthy (97)	Stool, Dental, Saliva	Metagenomic shotgun sequencing	↑ <i>Lactobacillus salivarius</i> , ↑ <i>Gordonibacter pamelaeeae</i> , ↑ <i>Clostridium asparagiforme</i> , ... , ↓ <i>Haemophilus</i> spp.	[28]





Figure 1. Gut microbiota contribute to the pathogenesis of RA. The healthy gut microbiota is in a homeostasis state that maintains integrity of the intestinal epithelial cell layer and has multiple symbiotic microbes to help in physiological functions. In genetically susceptible individuals, environmental factors can influence the gut microbiota causing changes in the types and abundance of microbiome (dysbiosis). The dysbiosis in gut microbiota, in association with genetic factors, may disrupt the innate and adaptive immune system and contribute to the development of RA via multiple molecular mechanisms. PSA, polysaccharide A; SCFAs, short-chain fatty acids; SAA, serum amyloid A; ATP, adenosine 5'-triphosphate; DCs, dendritic cells; IL, Interleukin; TGF-β, Transforming growth factor-beta; Treg cells, regulatory T cells; Th17 cells, T helper 17 cells.

Gut-microbiome and Host

- ✓ IBD
- ✓ Obesity
- ✓ Diabetes Mellitus
- ✓ NASH
- ✓ Autoimmunity
- ✓ Cancer

- **ESCHERICHIA COLI AIEC**



Produce una genotossina COLIBACTINA che danneggia il DNA ed è essenziale per lo sviluppo dei tumori.

- **BACTEROIDES FRAGILIS**



Attiva attraverso una tossina (BACTERIOLISINA) che si interpone ad una proteina *suppressor* del tumore β -caderina e attiva il sistema β -catenina che \uparrow VEFG, \uparrow COX₂ e quindi l'attecchimento e proliferazione del tumore.

- **FUSOBACTERIUM NUCLEATUM**



Presenta una adesina (FADA) che si trova sulla sua superficie, che si attacca e promuove l'inversione delle cellule tumorali intestinali.

Diet, GUT microbiota and Colonic Cancer

Diet

Modulate composition and metabolic activity of colon ecoflora

Clostridia and Bacteroides
increase the tumor
proliferative index

Lactobacilli and Bifidobacteria
protective role against the
cancerogenetic process

Diet, GUT Microbiota and carcinogens

Red meat



High dietary sulfur

Growth of sulfur-reducing bacteria
Desulfovibrio vulgaris

Free radicals

Hydrogen sulphide

Co-carcinogen

Impairs
cytochrome
oxidase

- Butyrate
utilization

- Syntesis of
mucus

- Methylation of DNA

Research Paper

Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism

Zhiliang Wei¹, Shougen Cao¹, Shanglong Liu¹, Zengwu Yao², Teng Sun³, Yi Li¹, Jiante Li¹, Dongfeng Zhang⁴, Yanbing Zhou¹

¹Department of General Surgery, Affiliated Hospital of Qingdao University, Qingdao, China

²Department of General Surgery, Yantai Yuhuangding Hospital, Yantai, China

³Department of General Surgery, Qingdao Municipal Hospital Group, Qingdao, China

⁴Department of Epidemiology and Health Statistics, Qingdao University Medical College, Qingdao, China

Correspondence to: Yanbing Zhou, **email:** zhoyanbing999@aliyun.com







Keywords: colorectal cancer, inflammation, intestinal microbiology, prognostic biomarker, prognosis

Received: February 24, 2016

Accepted: June 02, 2016


Published: June 15, 2016

Curve di sopravvivenza di Kaplan-Meier per i sopravvissuti totale (OS) e isopravvissuti non malati(DFS) in 180 pazienti CRC.





Wei Z et al; Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism; Oncotarget, 2016.

Immunoistochimica per l'analisi della espressione del gene KRAS, BRAF e MLH1 nei tessuti tumorali con diversa abbondanza rispettivamente di *B. fragilis*, *F. nucleatum* e *F.prausnitzii*.



Wei Z et al; Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism; Oncotarget, 2016.

Livelli di espressione dell'mRNA del *TNF*, *COX2*, *MMP9* and *CTNNB* nei tessuti cancerosi con diversa concentrazione di *B. fragilis*, *F. nucleatum* e *F. prausnitzii* analizzati con RT-PCR, e le proteine *TNF- α* , *COX-2*, *MMP-9*, β -catenina e *NF- κ B* analizzati con western blot.



Wei Z et al; Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism; Oncotarget, 2016.


Question 9

**May GUT bacteria interfere with
GI stem cells for regeneration?**

DIFFERENTIATION



PROLIFERATION



- Fully differentiated terminal cells
- Proliferating/differentiating cells
- Stem cells




REPLICATION STAGES

GI TURNOVER

➤ The GI epithelium experiences **continuous cell loss**, also enhanced by the high rates of mechanical attrition

➤ Most of the epithelial cells are **replaced every 2-5 days**



➤ The GI renewal depends on a small population of **multipotent GI-SCs** situated within the intestinal crypts and the gastric glands (*unitarian hypothesis*)



MARKERS OF GISCs

- Potential markers of GISCs:
 - *Musashi-1 (Msi-1)*
 - *Enhancer of Split Homolog-1 (Hes)*,
 - *side population*,
 - *FoxP4*,
 - *Eph*,
 - *EphA6*
- Signaling pathways controlling GISCs fate:
 - *Wnt/β-catenin*
 - *T-cell factor (TCF)/lymphoid enhancing factor (LEF)*

Robert K. J. Anat (2008)




POSSIBLE ORIGINS OF GISCs


GISCs are **mainly endogenous gut cells**

However, extra-intestinal cells (such as **bone marrow SCs**) can colonize the GI epithelium and **contribute to the intestinal repopulation** by:

- *giving rise to GISCs*
- *providing supporting elements (i.e. myofibroblasts, which play an important role in the regulation of GI-SC niche)*



Activation of **Wnt signalling pathway** in CD133+ small bowel stem cells → neoplastic transformation of the small intestinal mucosa.





Zhu L Nature. 2008

CD133+ stem cells give rise to small bowel tumors *via* Wnt activation

Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation

Liqin Zhu¹, Paul Gibson¹, D. Spencer Currie¹, Yiai Tong¹, Robert J. Richardson¹, Ildar T. Bayazitov¹, Helen Poppleton¹, Stanislav Zakharenko¹, David W. Ellison² & Richard J. Gilbertson^{1,3}

CD133 (Prominin1) is a marker of Lgr5⁺ stem cells in the small intestine




Elimination of Colon Cancer in Germ-free Transforming Growth Factor Beta 1-deficient Mice

Sandra J. Engle, Ilona Ormsby, Sharon Pawlowski, et al.

Cancer Res 2002;62:6362-6366.

- Patients with ulcerative colitis are at risk for colon cancer and frequently have microsatellite instability, which is usually associated with inactivation of transforming growth factor (TGF) signaling.
- TGF-1 deficiency in mice can lead to colon cancer (precancerous lesions having submucosal inflammation and hyperplastic crypts)
- Germ-free TGF-1-deficient mice are free of inflammation, hyperplasia, and cancer, but when reintroduced into a *Helicobacter hepaticus*-containing specific pathogen-free room, these lesions reappear




Elimination of Colon Cancer in Germ-free Transforming Growth Factor Beta 1-deficient Mice

Sandra J. Engle, Ilona Ormsby, Sharon Pawlowski, et al.

Cancer Res 2002;62:6362-6366.


-Because adenoma/carcinoma but not inflammation/hyperplasia is dependent on the genetic backgrounds tested, colitis is required, but not sufficient, for carcinogenesis.

- This animal model should provide insight into the protective role of TGF-1 in early stages of ulcerative colitis-associated human colon cancer



(Tgfb1)-null mice develop colonic cancer in the presence of conventional gut microbiota

FODMAP



F: fermentabili

O: oligosaccaridi

D: disaccaridi (lattosio, fruttani, fruttosio, galattani)

M: monosaccaridi

A: and

P: polyols (sorbitolo, mannitolo, xilitolo, maltitolo, lattulosio)




✓ Osmoticamente attivi

✓ Scarsamente assorbiti nell'intestino

✓ Rapidamente fermentati nel tenue

DIETA FODMAP

	Fruttosio	Lattosio	Oligosaccaridi (fruttani-galattani)	Polioli
Fonti alimentari ad ALTO CONTENUTO di FODMAP	<p>Frutta: mele, pere, pesche, mango, anguria</p> <p>Miele</p> <p>Dolcificanti: fruttosio, sciroppo di mais</p> <p>Alte dosi di fruttosio: concentrati di frutta, conserve di frutta, succhi di frutta, frutta secca</p>	<p>Latte: mucca, capra, pecora, gelati</p> <p>Formaggi: morbidi e freschi (per es. ricotta)</p>	<p>Verdure: carciofi, asparagi, barbabietole, cavolini di Bruxelles, broccoli, cavoli, finocchio, aglio, gombo, cipolle, piselli, scalogno</p> <p>Cereali: Frumento e segale se consumati in grandi quantità (pane, pasta, couscous, crackers, biscotti)</p> <p>Legumi: ceci, lenticchie, fagioli, fave</p> <p>Frutta: anguria, pesche bianche, cachi</p>	<p>Frutta: mele, albicocche, ciliegie, pere, pesche, susine, prugna, anguria</p> <p>Verdura: avocado, cavolfiori, funghi, piselli</p> <p>Dolcificanti: sorbitolo, mannitolo, xilitolo e altri che terminano in -olo</p>
Fonti alimentari a BASSO CONTENUTO di FODMAP	<p>Frutta: banana, mirtillo, pompelmo, uva, melone, kiwi, limone, mandarino, arancia, lampone, fragola</p> <p>Sostitutivi del miele: sciroppo d'acero</p> <p>Dolcificanti: tutti eccetto i polioli</p>	<p>Latte: latte delattosato, di soia, di riso</p> <p>Formaggi: formaggi duri e stagionati</p> <p>Sostituti del gelato: sorbetti</p> <p>Burro</p>	<p>Verdure: germogli di bambù, sedano, peperoni, melanzane, fagiolini, lattuga, erba cipollina, zucca, cipolla verde, pomodoro</p> <p>Cereali: prodotti senza glutine e farro</p>	<p>Frutta: banana, mirtillo, pompelmo, kiwi, mandarino, limone, arancia, uva, lampone, fragola</p> <p>Dolcificanti: zucchero (saccarosio), glucosio, dolcificanti che non terminano in -olo</p>



Downloaded from <http://gut.bmj.com/> on November 6, 2015 - Published by group.bmj.com

ORIGINAL ARTICLE

Diets that differ in their FODMAP content alter the colonic luminal microenvironment

Emma P Halmos,^{1,2} Claus T Christophersen,³ Anthony R Bird,³ Susan J Shepherd,¹ Peter R Gibson,^{1,2} Jane G Muir^{1,2}

Figure 1 Comparison of faecal indices with the two interventional diets in subjects with IBS and healthy subjects. (A) Changes in pH, total and major short-chain fatty acids (SCFAs) and branched-chain fatty acids (BCFAs); (B) total and specific absolute bacterial abundance; and (C) relative bacterial abundance. All data are presented as a ratio of low Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAP) to typical Australian diet and analysed by Wilcoxon matched-pairs signed rank test. Statistically significant differences between the diets are indicated with an asterisk based upon $p \leq 0.05$ for faecal pH, $p \leq 0.006$ for SCFA concentrations $p \leq 0.005$ for absolute and $p \leq 0.006$ for relative bacterial abundance after Bonferroni correction.



... ed il microbiota ha un suo ruolo nella malattia celiaca?

Intestinal Microbiota and Probiotics in Celiac Disease

Luís Fernando de Sousa Moraes, Lukasz Marcin Grzeskowiak, Tatiana Fiche de Sales Teixeira, Maria do Carmo Gouveia Peluzio
 Department of Nutrition and Health, Federal University of Viçosa, Viçosa, Minas Gerais, Brazil




FIG 1 Different cereal-derived products and intestinal inflammation in CD subjects. Consumption of food-derived products containing wheat, barley, and rye by individuals genetically susceptible to CD leads to villous atrophy, intestinal inflammation, and disassembly of tight junctions.




FIG 2 Inflammation process and possible routes of probiotic action in the maintenance of CD. In CD patients, increased epithelial tight junction permeability ("leaky gut") favors the entrance of non-well-digested gluten peptides from the lumen to the lamina propria. Once there, they are deamidated by the tissue transglutaminase (tTG) enzyme and presented to CD4⁺ T immune cells by the human leukocyte antigen (HLA) in antigen-presenting cells (APCs), which in CD patients is often of the haplotypes DQ2 and DQ8. Thereafter, Th1 and Th2 immune responses are triggered, resulting in autoimmunity, mucosal inflammation, and the growth of unfavorable microbiota, worsening the prognosis of disease. Three large arrows indicate where probiotics could act.

Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms

A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial

Ruggiero Francavilla, MD, PhD, Maria Piccolo, PhD,†*

*Antonio Francavilla, MD, PhD,‡ Lorenzo Polimeno, PhD,**

*Francesco Semeraro, MD,§ Fernanda Cristofori, MD,**

*Stefania Castellaneta, MD,|| Michele Barone, MD, PhD,¶ Flavia Indrio, MD,**

Marco Gobetti, PhD,# and Maria De Angelis, PhD†

J Clin Gastroenterol • Volume 53, Number 3, March 2019

Probiotics in CD Patients With GI Symptoms




FIGURE 1. Study design. BSFS indicates Bristol Stool Form Scale; GSRS, Gastrointestinal Symptom Rating Scale; IBS-SSS, Irritable Bowel Syndrome Severity Scoring System; QOL, Quality of Life; R, randomization.




FIGURE 2. Flow diagram of patients in the trial from eligibility to the end of follow-up. GFD indicates gluten-free diet; TTG-IgA, tissue transglutaminase immunoglobulin-A.




FIGURE 3. Relative abundance of the most relevant metabolically active bacterial phyla found in feces of the fecal samples of celiac disease patients with irritable bowel syndrome at baseline (W2), after 6 weeks (W8) of treatment with probiotics or placebo, and at the end of follow-up (W14). NS indicates not significant; OTU, operational taxonomic unit; P, placebo; T, treated.









FIGURE 4. Metabolically active *Bifidobacterium* genus found in feces of the fecal samples of celiac disease patients with irritable bowel syndrome at baseline (W2), after 6 weeks (W8) of treatment with probiotics or placebo, and at the end of follow-up (W14). NS indicates not significant; OTU, operational taxonomic unit; P, placebo; T, treated.





Endoscopic finding of diverticular inflammation in patients with symptomatic diverticular disease

Assessment of Fecal Microbiota and Fecal Metabolome in Symptomatic Uncomplicated Diverticular Disease of the Colon

Antonio Tursi, MD,* Paola Mastromarino, MD,† Daniela Capobianco, BSci,‡
 Walter Elisei, MD,‡ Alfredo Micheli, MD,§ Giorgio Capuani, PhD,§
 Alberta Tomassini, PhD,§ Giuseppe Campagna, MS, PhD,||
 Marcello Picchio, MD,¶ GianMarco Giorgetti, MD,#
 Federica Fabiocchi, MD,# and Giovanni Brandimarte, MD**




Akkermansia muciniphila



(Giorno 0)



2 settimane di
Trattamento con:
Probiotico (DSF)[®] (P) o
Rifaximina (R) o Mesalazina (M)
o Fibre (F)



(Giorno 14)



(Giorno 44)

Il Microbiota ed il Metaboloma
cambiano sotto trattamento nei
pazienti con SUD, confermando il
possibile ruolo della
disbiosi/dismetabolismo nella
patogenesi della malattia



Significativa riduzione del dolore
addominale in fossa iliaca sinistra
durante il follow-up ($p<0.0001$), ma con
nuovo incremento a T3.

II MODELLO DI PCA DI T0 vs T1 DIFFERISCE SIGNIFICATIVAMENTE COME BATTERI E METABOLITE




La quantità totale di *Akkermansia muciniphila* si
riduceva a T1 ($p=0.017$) e T2 ($p=0.026$), mentre a T3
tornava simile ai livelli di T0 ($p=0.09$).

MA GUT MICROBIOTA AGISCE
SULLA BARRIERA ENCEFALICA
DELL'ANZIANO??

Proinflammatory cytokines, sickness behavior, and Alzheimer disease

Figure 1. Frequency distribution of neuropsychiatric features in subjects with Alzheimer disease over the 6-month follow-up period by low or high levels of tumor necrosis factor- α (TNF α)




* $p \leq 0.05$, ** $p \leq 0.01$, adjusted for baseline age, gender, Alzheimer's Disease Assessment Scale Cognitive subscale score, and presence of delirium during follow-up.


Proinflammatory cytokines, sickness behavior, and Alzheimer disease

Figure 2


Frequency distribution of neuropsychiatric features in subjects with Alzheimer disease over the 6-month follow-up period by low or high levels of interleukin-6 (IL-6)



* $p \leq 0.05$, ** $p \leq 0.01$, adjusted for baseline age and gender.



Current Biology 26, 1–6, June 6, 2016 © 2016 Elsevier Ltd.



**« La morte si trova nel viscere ...
e la cattiva digestione
è la radice di ogni male....»**

grazie dell'attenzione!!!!

gianmarcogiorgetti@hotmail.com